MY159803A - Treating dyspnea associated with accurate heart failure with relaxin - Google Patents

Treating dyspnea associated with accurate heart failure with relaxin

Info

Publication number
MY159803A
MY159803A MYPI2010005049A MYPI2010005049A MY159803A MY 159803 A MY159803 A MY 159803A MY PI2010005049 A MYPI2010005049 A MY PI2010005049A MY PI2010005049 A MYPI2010005049 A MY PI2010005049A MY 159803 A MY159803 A MY 159803A
Authority
MY
Malaysia
Prior art keywords
relaxin
heart failure
accurate heart
dyspnea associated
treating dyspnea
Prior art date
Application number
MYPI2010005049A
Other languages
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of MY159803A publication Critical patent/MY159803A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2010005049A 2008-05-16 2009-05-15 Treating dyspnea associated with accurate heart failure with relaxin MY159803A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
MY159803A true MY159803A (en) 2017-02-15

Family

ID=40834101

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2010005049A MY159803A (en) 2008-05-16 2009-05-15 Treating dyspnea associated with accurate heart failure with relaxin
MYPI2013004312A MY158327A (en) 2008-05-16 2013-11-28 Treating dyspnea associated with acute heart failure with relaxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2013004312A MY158327A (en) 2008-05-16 2013-11-28 Treating dyspnea associated with acute heart failure with relaxin

Country Status (30)

Country Link
US (7) US8053411B2 (OSRAM)
EP (2) EP2829280A1 (OSRAM)
JP (4) JP5651586B2 (OSRAM)
CN (3) CN102036679A (OSRAM)
AR (1) AR071810A1 (OSRAM)
AU (1) AU2009246114B2 (OSRAM)
BR (1) BRPI0913011A2 (OSRAM)
CA (1) CA2724540C (OSRAM)
CR (1) CR11749A (OSRAM)
CY (1) CY1116925T1 (OSRAM)
DK (1) DK2288373T3 (OSRAM)
EA (2) EA022948B1 (OSRAM)
ES (1) ES2546287T3 (OSRAM)
GB (2) GB2462221B (OSRAM)
HK (1) HK1202054A1 (OSRAM)
HR (1) HRP20150845T1 (OSRAM)
HU (1) HUE025483T2 (OSRAM)
IL (3) IL208992A (OSRAM)
MA (1) MA32389B1 (OSRAM)
MX (1) MX2010012450A (OSRAM)
MY (2) MY159803A (OSRAM)
NZ (3) NZ589009A (OSRAM)
PL (1) PL2288373T3 (OSRAM)
PT (1) PT2288373E (OSRAM)
SG (2) SG10201609580YA (OSRAM)
SI (1) SI2288373T1 (OSRAM)
TW (1) TWI386202B (OSRAM)
UA (1) UA99953C2 (OSRAM)
WO (1) WO2009140659A2 (OSRAM)
ZA (1) ZA201007449B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246112B2 (en) * 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX2012010382A (es) * 2010-03-10 2013-01-29 Univ Melbourne Modulacion de acuaporinas con relaxina.
US8501418B2 (en) * 2010-08-06 2013-08-06 Pronata N.V. Method of treating renal dysfunction based on perlecan as a biomarker
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2742296T3 (es) * 2010-08-17 2020-02-13 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
KR102107482B1 (ko) * 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
KR102299073B1 (ko) 2012-10-26 2021-09-09 치에시 파마슈티시 에스.피.아. 심부전에서 혈압을 조절하고 호흡곤란을 감소시키는 방법
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
AU2020214314B2 (en) 2019-01-31 2025-09-18 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
EP4580653A1 (en) 2022-08-31 2025-07-09 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
EP0675732B1 (en) * 1993-07-27 2006-06-28 Mario Bigazzi Use of relaxin in the manufacture of therapeutic agents
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
EP0845992B1 (en) 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
CA2397200C (en) * 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US20070202080A1 (en) 2004-03-30 2007-08-30 Industry-University Cooperation Foundation Yonsei Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
WO2007008907A2 (en) 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
JP5355561B2 (ja) 2007-07-12 2013-11-27 コンピュゲン エルティーディー． 生物活性ペプチドおよびその使用方法
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
AU2009246112B2 (en) 2008-05-16 2013-05-02 Corthera, Inc. Method of treating chronic heart failure

Also Published As

Publication number Publication date
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US20120040902A1 (en) 2012-02-16
MY158327A (en) 2016-09-30
CN102036679A (zh) 2011-04-27
US20130210730A1 (en) 2013-08-15
JP5651586B2 (ja) 2015-01-14
JP2011520918A (ja) 2011-07-21
HUE025483T2 (en) 2016-02-29
CR11749A (es) 2011-02-11
NZ701038A (en) 2016-01-29
TWI386202B (zh) 2013-02-21
US20170151311A1 (en) 2017-06-01
AU2009246114B2 (en) 2013-01-31
CN106177914A (zh) 2016-12-07
JP2016053040A (ja) 2016-04-14
HK1202054A1 (en) 2015-09-18
UA99953C2 (uk) 2012-10-25
JP5875646B2 (ja) 2016-03-02
US20100048475A1 (en) 2010-02-25
EA201001771A1 (ru) 2011-06-30
NZ598709A (en) 2013-09-27
US20150320834A1 (en) 2015-11-12
AR071810A1 (es) 2010-07-14
GB2459983B (en) 2010-04-28
CA2724540C (en) 2014-07-08
MX2010012450A (es) 2011-03-21
JP2015013870A (ja) 2015-01-22
JP5638044B2 (ja) 2014-12-10
WO2009140659A2 (en) 2009-11-19
WO2009140659A3 (en) 2010-07-22
TW200948353A (en) 2009-12-01
GB0918132D0 (en) 2009-12-02
GB2459983A (en) 2009-11-18
SG10201609580YA (en) 2016-12-29
DK2288373T3 (en) 2015-09-28
HK1187550A1 (zh) 2014-04-11
BRPI0913011A2 (pt) 2019-09-03
AU2009246114A1 (en) 2009-11-19
EP2288373A2 (en) 2011-03-02
JP2013040174A (ja) 2013-02-28
PL2288373T3 (pl) 2015-11-30
EA022948B1 (ru) 2016-03-31
US8053411B2 (en) 2011-11-08
CN103212063A (zh) 2013-07-24
ZA201007449B (en) 2011-06-29
HK1151229A1 (en) 2012-01-27
US8415301B2 (en) 2013-04-09
US20130116181A1 (en) 2013-05-09
US9579363B2 (en) 2017-02-28
US20120040903A1 (en) 2012-02-16
HK1139051A1 (en) 2010-09-10
CN103212063B (zh) 2015-07-22
US8372809B2 (en) 2013-02-12
EA201500552A1 (ru) 2016-07-29
CY1116925T1 (el) 2017-04-05
IL208992A (en) 2013-09-30
SI2288373T1 (sl) 2015-12-31
SG191587A1 (en) 2013-07-31
US9205132B2 (en) 2015-12-08
EP2829280A1 (en) 2015-01-28
ES2546287T3 (es) 2015-09-22
IL247351A0 (en) 2016-09-29
HRP20150845T1 (hr) 2015-11-06
PT2288373E (pt) 2015-10-19
IL208992A0 (en) 2011-01-31
CA2724540A1 (en) 2009-11-19
GB2462221A (en) 2010-02-03
EP2288373B1 (en) 2015-06-24
IL228244A (en) 2016-10-31
US9066916B2 (en) 2015-06-30
GB0908432D0 (en) 2009-06-24
GB2462221B (en) 2010-09-01
HK1140693A1 (en) 2010-10-22

Similar Documents

Publication Publication Date Title
MY159803A (en) Treating dyspnea associated with accurate heart failure with relaxin
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
NZ601167A (en) Treatment of cardiac conditions
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
MX342525B (es) Uso de antagonistas del receptor de adenosina a2b para tratar insuficiencia cardiaca y arritmia en pacientes post-infarto al miocardio.
MX2010006443A (es) TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
UA40165U (ru) Способ оценки уровня кортизола у больных с ишемической болезнью сердца
MD3987C2 (ro) Utilizare a Diosminei pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă
UA46804U (ru) Способ оценки уровня вазопрессина при хронической сердечной недостаточности
UA60249U (ru) Способ лечения острого инфаркта миокарда
UA41944U (ru) Способ прогнозирования выживания больных с хронической сердечной недостаточностью та систолической дисфункцией левого желудочка
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
Reynolds Cardiac resynchronization for heart failure: Its time has come
UA53527U (ru) Способ комплексного лечения хронической сердечной недостаточности у больных пожилого возраста с ишемической болезнью сердца
UA49567U (ru) Способ лечения хронических заболеваний кишечника у больных гипертонической болезнью
UA40164U (ru) Способ оценки активности антиоксидантной системы у больных хронической сердечной недостаточностью
UA107447C2 (uk) Спосіб оцінки ефективності лікування пропранололом хворих на ішемічну хворобу серця з стенокардією та артеріальною гіпертензією з порушенням діастолічної функції лівого шлуночка по "гіпертрофічному" типу